Table 5.

Presentations to PHC or hospital admissions secondary to exacerbation of airway disease or lower respiratory tract infections

Hospital and PHC presentation	SAMA/SABA (n=45)	LAMA/LABA (n=31)	+ICS (n=270)	P value
Any respiratory presentation	29 (64%)	25 (81%)	234 (87%)	0.002*
Total number of respiratory presentations	2 (1, 3) (1, 24)	2 (1, 2) (1, 6)	3 (2, 7) (1, 74)	<0.001*
Total presentation rate	0.22 (0.13, 0.35)	0.22 (0.13, 0.34)	0.4 (0.21, 0.73)	<0.001*
Any respiratory presentation to hospital	18 (40%)	16 (52%)	167 (62%)	0.017*
Total no of respiratory presentations to hospital	2 (1, 3) (1, 25)	2 (1, 2) (1, 5)	3 (2, 7) (1, 74)	0.001*
Hospital presentation rate	0.21 (0.13, 0.51)	0.21 (0.12, 0.28)	0.42 (0.21, 0.78)	0.004*
Any respiratory presentation to PHC	20 (44%)	15 (48%)	163 (60%)	0.079
Total no of respiratory presentations to PHC	1 (1, 2) (1, 3)	2 (1, 2) (1, 2)	2 (1, 2) (1, 8)	0.141
PHC presentation rate	0.14 (0.11, 0.21)	0.2 (0.11, 0.23)	0.2 (0.12, 0.27)	0.428
Mortality	2 (4%)	4 (13%)	22 (8%)	0.399

Parameters displayed as number (%), median (IQR) (minimum, maximum).

P value obtained via χ² or Fisher’s exact test (cases where cells values were <10) for categorical parameters, Kruskal-Wallis rank test for continuous parameters.

*p<0.05.

ICS, inhaled corticosteroids; LABA, long-acting β-agonists; LAMA, long-acting muscarinic antagonists; PHC, primary health centre; SABA, short-acting bronchodilator; SAMA, short-acting muscarinic antagonists.